美国 · SEC FORM 4
Kura Oncology, Inc.
KURA · Nasdaq · CIK 0001422143 · Healthcare · Biotechnology
内部人信号
2 qualifying P purchase groups
当前 180 天评分窗口
20 同一窗口内观察到的 Form 4 交易行
17 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
Roles in the peak window: President and CEO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-08-24 · WILSON TROY EDWARD.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 14,419,736
- 上期报告
- 14,820,592
- 日均成交量
- 1,864,560
- 回补天数
- 7.7
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-24 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 100,000 | USD 12.39 | USD 1,239,000 | SEC 申报 ↗ |
| 2026-08-17 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 100,000 | USD 11.12 | USD 1,112,000 | SEC 申报 ↗ |
| 2025-09-08 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 50,000 | USD 8.20 | USD 410,000 | SEC 申报 ↗ |
| 2025-08-13 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 13,494 | USD 6.64 | USD 89,600 | SEC 申报 ↗ |
| 2025-08-12 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 36,506 | USD 5.85 | USD 213,560 | SEC 申报 ↗ |
| 2023-06-16 | Malley Thomas | 买入 (P) | Common stock | 50,000 | USD 11.50 | USD 575,000 | SEC 申报 ↗ |
Form 4 申报证据
57 transaction lines in the latest 365-day window; 192 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Powl Brian T. | 卖出 (S) | Common Stock | 15,430 | USD 10.75 | USD 165,872 | SEC 申报 ↗ |
| 2026-09-29 | Leoni Mollie | 卖出 (S) | Common Stock | 28,802 | USD 10.75 | USD 309,622 | SEC 申报 ↗ |
| 2026-09-29 | FORD KATHLEEN | 卖出 (S) | Common Stock | 3,668 | USD 10.75 | USD 39,431 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Powl Brian T. | 卖出 (S) | Common Stock | 15,430 | USD 10.75 | USD 165,872 | SEC 申报 ↗ |
| 2026-09-29 | Leoni Mollie | 卖出 (S) | Common Stock | 28,802 | USD 10.75 | USD 309,622 | SEC 申报 ↗ |
| 2026-09-29 | FORD KATHLEEN | 卖出 (S) | Common Stock | 3,668 | USD 10.75 | USD 39,431 | SEC 申报 ↗ |
| 2026-09-28 | Powl Brian T. | 卖出 (S) | Common Stock | 17,020 | USD 10.53 | USD 179,190 | SEC 申报 ↗ |
| 2026-09-28 | Leoni Mollie | 卖出 (S) | Common Stock | 12,448 | USD 10.50 | USD 130,704 | SEC 申报 ↗ |
| 2026-09-28 | FORD KATHLEEN | 卖出 (S) | Common Stock | 6,906 | USD 10.50 | USD 72,513 | SEC 申报 ↗ |
| 2026-09-28 | DOYLE THOMAS JAMES | 卖出 (S) | Common Stock | 4,607 | USD 10.50 | USD 48,374 | SEC 申报 ↗ |
| 2026-09-28 | Bair Teresa Brophy | 卖出 (S) | Common Stock | 8,442 | USD 10.50 | USD 88,641 | SEC 申报 ↗ |
| 2026-09-24 | Burrows Francis | 卖出 (S) | Common Stock | 20,726 | USD 10.83 | USD 224,463 | SEC 申报 ↗ |
| 2026-09-24 | Burrows Francis | 期权行权/转换 (M) | Common Stock | 30,000 | USD 6.15 | USD 184,500 | SEC 申报 ↗ |
| 2026-08-24 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 100,000 | USD 12.39 | USD 1,239,000 | SEC 申报 ↗ |
| 2026-08-21 | Powl Brian T. | 卖出 (S) | Common Stock | 4,345 | USD 11.89 | USD 51,662 | SEC 申报 ↗ |
| 2026-08-19 | Bair Teresa Brophy | 卖出 (S) | Common Stock | 31,487 | USD 12.63 | USD 397,681 | SEC 申报 ↗ |
| 2026-08-17 | WILSON TROY EDWARD | 买入 (P) | Common Stock | 100,000 | USD 11.12 | USD 1,112,000 | SEC 申报 ↗ |
| 2026-06-18 | Leoni Mollie | 卖出 (S) | Common Stock | 84,929 | USD 9.82 | USD 834,003 | SEC 申报 ↗ |
| 2026-05-21 | Powl Brian T. | 卖出 (S) | Common Stock | 10,000 | USD 11.00 | USD 110,000 | SEC 申报 ↗ |
| 2026-05-19 | Powl Brian T. | 卖出 (S) | Common Stock | 339 | USD 9.21 | USD 3,122 | SEC 申报 ↗ |
| 2026-05-19 | FORD KATHLEEN | 卖出 (S) | Common Stock | 2,257 | USD 9.08 | USD 20,494 | SEC 申报 ↗ |
| 2026-05-18 | Bair Teresa Brophy | 卖出 (S) | Common Stock | 2,256 | USD 9.38 | USD 21,161 | SEC 申报 ↗ |
| 2026-03-23 | WILSON TROY EDWARD | 期权行权/转换 (M) | Common Stock | 6,103 | USD 6.15 | USD 37,533 | SEC 申报 ↗ |
| 2026-03-18 | Malley Thomas | 期权行权/转换 (M) | Common Stock | 10,000 | USD 3.12 | USD 31,200 | SEC 申报 ↗ |
| 2026-01-27 | Powl Brian T. | 卖出 (S) | Common Stock | 6,414 | USD 8.46 | USD 54,262 | SEC 申报 ↗ |
| 2026-01-27 | Leoni Mollie | 卖出 (S) | Common Stock | 8,180 | USD 8.46 | USD 69,203 | SEC 申报 ↗ |
| 2026-01-27 | FORD KATHLEEN | 卖出 (S) | Common Stock | 1,813 | USD 8.46 | USD 15,338 | SEC 申报 ↗ |
| 2026-01-27 | DOYLE THOMAS JAMES | 卖出 (S) | Common Stock | 4,916 | USD 8.46 | USD 41,589 | SEC 申报 ↗ |
| 2026-01-27 | Burrows Francis | 卖出 (S) | Common Stock | 1,311 | USD 8.46 | USD 11,091 | SEC 申报 ↗ |
| 2026-01-27 | Bair Teresa Brophy | 卖出 (S) | Common Stock | 11,208 | USD 8.46 | USD 94,820 | SEC 申报 ↗ |
| 2026-01-02 | Powl Brian T. | 奖励/授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Leoni Mollie | 奖励/授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | FORD KATHLEEN | 奖励/授予 (A) | Common Stock | 50,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | KURA |
| CIK | 0001422143 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 192 transaction lines from 2020-02-11 to 2026-09-29 6 P purchase lines · 108 S sale lines · 78 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.